Please type your full address or zip code below.

Cancel Submit

Mobeen H. Rathore, M.B.B.S. (M.D.), CPE, FACPE, FIDSA, FAAP

Professor
Department of Pediatrics
Division of Pediatric Infectious Diseases and Immunology

Associate Chair, Department of Pediatrics; Chief, Division of Pediatric Infectious Diseases and Immunology; Director, UF Center for HIV/AIDS Research, Education and Service (UF CARES)

Specializes in Pediatric Infectious Diseases

Speaks English, Punjabi and Urdu

Specialty

<a href = 'http://ufhealthjax.org/pediatric-infectious-diseases/' target = '_blank'>Pediatric Infectious Diseases</a>

Board Certifications

Pediatrics
Certified Physician Executive

Professional Education

Medical Education: King Edward Medical College Punjab University, Lahore, Pakistan
Residency: Pediatrics, Children's Hospital Medical Center, Akron, OH, USA
Fellowship: Pediatric Infectious Diseases, St. Louis University School of Medicine, St Louis, MO, USA
Fellowship: Pediatric Infectious Diseases, Washington University, St Louis, MO, USA

Interests

Clinical Special Interests: Immunizations, pediatric HIV; infectious diseases in children
Research Special Interests: Immunizations; hospital epidemiology; infectious diseases in children, HIV/AIDS, MRSA

Publications

Search for publications by Mobeen H. Rathore, M.B.B.S. (M.D.), CPE, FACPE, FIDSA, FAAP

Please note: The resulting entries may not reflect a complete or accurate listing for Mobeen H. Rathore, M.B.B.S. (M.D.), CPE, FACPE, FIDSA, FAAP Many journals are not indexed by PubMed, and there may be articles by other authors of the same name listed by this search.

30.347047 -81.664392 UF Health CARES – Jacksonville
3rd Floor, Clinical Center
655 West 8th Street
Jacksonville, FL 32209

Appointment: (904) 244-2120
Referral: (904) 244-2120
Referral Fax: (904) 244-2896

30.335630 -81.664770 UF Health CARES/Rainbow at CMS Building
910 N. Jefferson Street
Jacksonville, FL 32209

Appointment: (904) 244-2121
Referral: (904) 244-2121
Referral Fax: (904) 244-2896

30.316274 -81.664128 UF Health Pediatric Multispecialty Center – Prudential Drive
Aetna Building, Suite 1900
841 Prudential Drive
Jacksonville, FL 32207

Appointment: (904) 633-0920
Referral: (904) 633-0920
Referral Fax: (904) 633-0921

30.315312 -81.663836 Wolfson Children's Hospital
800 Prudential Drive
Jacksonville, FL 32207

Appointment: (904) 202-8000
Referral: (904) 633-0780

Academic Office

910 N. Jefferson Street, L13
Jacksonville, FL 32209
(904) 798-4179
mobeen.rathore@jax.ufl.edu

Executive Assistant
Karen Hlubek
(904) 798-4179
karen.hlubek@jax.ufl.edu

Gilead GS-US-380-1474: A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/ Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children

Purpose: To test the safety, effectiveness, and pharmacokinetics of a new HIV medication, GS-9883.
IMPAACT P1097: Raltegravir Pharmacokinetics and Safety in Neonates, Version 2.0, dated 22 January 2014

Purpose: The purpose of this study is to find out if raltegravir, one of the drugs you are taking while pregnant for treatment of your HIV infection and to prevent passing HIV to your unborn baby, is getting into your unborn baby.
IMPAACT P1107: Cord Blood Transplantation with CCR5^32 Donor Cells in HIV-Infected Subjects who Require Bone Marrow Transplantation for any Indication and its Observed Effects on HIV-1 Persistence

Purpose: This study is being done to see what happens to the HIV virus when an HIV-infected person receives a transplant with known CCR5632 cells. We want to know if the HIV virus is suppressed (reduced) or removed from the body or if it stays in the body after the transplant. This study will also check how the cord blood cells grow in the body after transplant and whether there is any reaction of the body against the cells (graft versus host reaction) and the overall safety of the transplant in a participant who has HIV infection.
IMPAACT P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study

Purpose: Emerging data (ie. Recently reported "Mississippi Baby") suggests that very early therapy in high-risk HIV-exposure from untreated maternal HIV infection may attenuate HIV reservoir formation or block HIV persistence and provides the rationale to develop a proof-of-concept study of very early ART to achieve HIV remission/functional cure in infants. This study will specifically address the hypothesis that very early therapy in HIV-infected neonates prevents establishment of HIV resevoirs, including the long-lived resting memory CD4+ T cell latent reservoir, possibly permitting long-term control of HIV replication of ART, leading to HIV remission.
IMPACCT 1077 HS: HAART Standard Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere), Version 2.0, Dated October 9, 2012

Purpose: The purpose of this study is to determine if women who received HAART during pregnancy to reduce the chance of having a baby with HIV, and continue it after delivery will have less chance of getting sick from HIV infection than women who only receive HAART during pregnancy and then stop after delivery.

Showing 1 to 5 of 7

1 2

News

In the Media

Drag

0:00 / 0:00

QUICK LINKS

MAIN MENU

CONNECT WITH US

University of Florida

College of Medicine – Jacksonville

UNIVERSITY of FLORIDA

Continuing Medical Education

Faculty Development

Simulation Education

Education Programs at UF Health

Clinical Trials

Additional Resources

Office of the Dean

Development & Alumni Affairs

Mobeen H. Rathore, M.B.B.S. (M.D.), CPE, FACPE, FIDSA, FAAP